Select Publications

Conference Papers

Roberts SK; Ferenci P; Yoshihara M; Crawford DH; Sieverf W; McCaughan GW; Cheng W; Weltman M; Rawlinson WD; McCloud PI; Rizkalla B; Dore GJ, 2010, 'NON-SVR TO PEGINTERFERON ALFA-2A THERAPY AND RIBAVIRIN IS SRONGLY PREDICTED BY BASELINE FACTORS AND WEEK 8 ON-TREATMENT VIRAL LOAD IN HCV GENOTYPE (GT) 1 PATIENTS: NEW INSIGHTS FROM CART ANALYSIS OF THE CHARIOT STUDY', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 801A - 802A, presented at 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 29 October 2010 - 02 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000288775601314&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Marcellin P; Reddy KR; Roberts SK; Jensen DM; Harrison SA; Hadziyannis SJ; Dore G; Diago M; Weltman MD; Solsky J; Tietz A; Rizzetto M, 2010, 'Peginterferon Alfa-2a (40KD) Has a Wide Safety Margin in Patients Infected With Hepatitis C Virus Genotype 1: Pooled Data From Four Randomized Multicenter Studies', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, pp. S844 - S844, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000475844804188&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Matthews GV; Grebely J; Hellard M; Yeung B; Marks P; Rawlinson W; Kaldor J; Dore G, 2010, 'DIFFERENCES IN EARLY VIROLOGICAL DECLINE IN INDIVIDUALS TREATED WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV SUGGEST A POTENTIAL BENEFIT FOR THE USE OF RIBAVIRIN', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Vienna, AUSTRIA, pp. S28 - S28, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, AUSTRIA, 14 April 2010 - 18 April 2010, http://www.journal-of-hepatology.eu/article/S0168-8278(10)60062-1/abstract

Grebely J; Dore GJ; van der Loeff MS; Cox AL; Bruneau J; Kim AY; Lloyd AR; Hellard M; Page K; Prins M, 2010, 'FACTORS ASSOCIATED WITH SPONTANEOUS CLEARANCE DURING ACUTE HEPATITIS C VIRUS INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, AUSTRIA, Vienna, pp. S411 - S411, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 14 April 2010 - 18 April 2010, http://dx.doi.org/10.1016/S0168-8278(10)61064-1

Matthews GV; Grebely J; Hellard M; Yeung B; Marks P; Rawlinson W; Kaldor J; Dore GJ, 2010, 'WEEK 4 HCV RNA IS THE OPTIMAL PREDICTOR OF SVR IN BOTH HIV POSITIVE AND NEGATIVE SUBJECTS WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, AUSTRIA, Vienna, pp. S116 - S116, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 14 April 2010 - 18 April 2010, http://dx.doi.org/10.1016/S0168-8278(10)60278-4

McCaughan GW; Roberts SK; Weltman M; Crawford DH; Sievert W; Cheng W; Rawlinson W; Yoshihara M; McCloud PI; Rizkalla B; Dore GJ, 2009, 'ADVANCED FIBROSIS IN GENOTYPE 1 HCV INFECTED PATIENTS RECEIVING ANTIVIRAL THERAPY IS ASSOCIATED WITH VIROLOGIC RELAPSE INDEPENDENT OF RAPID (RVR) AND EARLY (EVR) VIROLOGIC RESPONSE', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1027A - 1028A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001564&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Weltman M; Dore GJ; Sievert W; McCaughan GW; Crawford DH; Cheng W; Rawlinson W; Yashihara M; McCloud PI; Rizkalla B; Roberts SK, 2009, 'BASELINE AND ONTREATMENT PREDICTORS OF SVR TO PEGINTERFERON ALFA-2A THERAPY AND RIBAVIRIN IN HCV GENOTYPE (GT) 1 TREATMENT NAIVE PATIENTS: NEW INSIGHTS FROM THE CHARIOT STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1033A - 1034A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001574&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Matthews G; Grebely J; Pham ST; Hellard M; Marks P; Rawlinson W; Kaldor J; Lloyd AR; White PA; Dore GJ, 2009, 'EPIDEMIOLOGY OF RECENTLY ACQUIRED HEPATITIS C VIRUS (HCV) INFECTION IN HCV AND HCV/HIV INFECTED PARTICIPANTS IN THE ATAHC STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 668A - 668A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000775&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Iser DM; Boyd AJ; Avihingsanon A; Thompson AL; Nguyen T; Matthews G; Bowden S; Locarnini S; Slavin J; Desmond PV; Dore GJ; Ruxrungtham K; Lewin SR, 2009, 'NO INCREASE IN INTRAHEPATIC MONONUCLEAR CELL OR STELLATE CELL ACTIVATION IN HIV-HBV CO-INFECTED INDIVIDUALS WITH ADVANCED HIV AND MILD LIVER DISEASE', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 993A - 994A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001493&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Marcellin P; Jensen DM; Roberts SK; Hadziyannis SJ; Dore GJ; Diago M; Weltman M; McCaughan GW; Cheng W; Crawford DH; Sievert W; Rawlinson W; Solsky J; Tietz A; Rizzetto M, 2009, 'PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha 2A) HAS A WIDE SAFETY MARGIN IN COMBINATION WITH RIBAVIRIN (RBV) 1000/1200 MG/DAY IN PATIENTS INFECTED WITH HCV GENOTYPE 1: POOLED ANALYSIS OF DATA FROM FOUR RANDOMIZED MULTICENTER STUDIES', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1030A - 1031A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001569&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Roberts SK; Ngu MC; Strasser SI; George J; Dore GJ; Locarnini S; Sasadeusz J; Sievert W; Peschell KJ; Mitchell K; Elsome AM, 2009, 'PREVALENCE AND NATURE OF VIRAL MUTATIONS IN CHRONIC HEPATITIS B (CHB) PATIENTS ON ORAL ANTIVIRAL THERAPY (AVT): THE CHARM STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 488A - 489A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000390&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sievert W; Dore GJ; McCaughan GW; Yoshihara M; Crawford DH; Cheng W; Weltman M; Rawlinson W; Rizkalla B; McCloud PI; Roberts SK, 2009, 'SIGNIFICANT HEMOGLOBIN (HB) DECLINE DURING PEGYLATED INTERFERON AND RIBAVIRIN THERAPY IN HCV GENOTYPE 1 IS ASSOCIATED WITH SUSTAINED VIROLOGIC RESPONSE (SVR): AN ANALYSIS FROM THE CHARIOT STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1020A - 1021A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001552&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dore GJ; Hellard M; Matthews G; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan GW; White PA; Ffrench RA; Rawlinson W; Lloyd AR; Kaldor J, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 723A - 723A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000887&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Iser DM; Boyd A; Avihingsanon A; Thompson AJ; Nguyen T; Matthews GV; Bowden S; Locarnini SA; Slavin J; Desmond PV; Dore GJ; Ruxrungtham K; Lewin SR, 2009, 'No increase in intrahepatic mononuclear or stellate cell activation in HIV-HBV co-infected individuals', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A292 - A292, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270551200196&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Roberts SK; Ngu MC; Strasser SI; George J; Dore GJ; Locarnini SA; Sasadeusz JJ; Sievert W; Peschell K; Mitchell K, 2009, 'Prevalence and characteristics of hepatitis B virus (HBV) mutations in chronic hepatitis B (CHB) patients on oral antiviral therapy (AVT): the charm study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A296 - A296, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270551200207&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Cheng WSC; Roberts S; Weltman M; Crawford DHG; Sievert W; McCaughan G; Rawlinson W; Desmond P; Yoshihara M; Rizkalla B; DePamphilis J; Marks P; Dore GJ, 2009, 'EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A 360 mu G/WEEK IN COMBINATION WITH RIBAVIRIN IN HEPATITIS C GENOTYPE I PATIENTS WITH CIRRHOSIS: ANALYSIS FROM THE CHARIOT STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, DENMARK, Copenhagen, pp. S221 - S221, presented at 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, DENMARK, Copenhagen, 22 April 2009 - 26 April 2009, http://dx.doi.org/10.1016/S0168-8278(09)60603-6

Roberts S; Weltman M; Crawford DHG; Cheng WSC; Sievert W; McCaughan G; Desmond P; Rawlinson W; Marks P; Yoshihara M; Rizkalla B; DePamphilis J; Dore GJ, 2009, 'HIGH-DOSE PEGINTERFERON ALFA-2A (40KD) INDUCTION THERAPY AND STANDARD RIBAVIRIN ENHANCES EARLY BUT NOT SUSTAINED VIROLOGICAL RESPONSES IN HCV GENOTYPE 1 PATIENTS: FINAL CHARIOT STUDY RESULTS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, DENMARK, Copenhagen, pp. S50 - S51, presented at 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, DENMARK, Copenhagen, 22 April 2009 - 26 April 2009, http://dx.doi.org/10.1016/S0168-8278(09)60126-4

Grebely J; Raffa J; Lai C; Krajde M; Fischer B; Kerr T; Dore G; Tyndall M, 2009, 'IMPACT OF HEPATITIS C VIRUS INFECTION ON LIVER-RELATED MORTALITY IN A LARGE COMMUNITY-BASED COHORT OF INNER CITY RESIDENTS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, DENMARK, Copenhagen, pp. S152 - S152, presented at 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, DENMARK, Copenhagen, 22 April 2009 - 26 April 2009, http://dx.doi.org/10.1016/S0168-8278(09)60404-9

Baleriola C; Rawlinson W; Chaverot S; Stelzer-Braid S; Yoshihara M; Rizkalla B; Dubois D; Sievert W; McCaughan G; Crawford DHG; Weltman M; Cheng WSC; Dore GJ; Roberts S, 2009, 'IMPACT OF LOW-LEVEL HEPATITIS C VIRAEMIA AT WEEK 24 ON HCV TREATMENT RESPONSE IN GENOTYPE 1 PATIENTS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, DENMARK, Copenhagen, pp. S220 - S220, presented at 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, DENMARK, Copenhagen, 22 April 2009 - 26 April 2009, http://dx.doi.org/10.1016/S0168-8278(09)60600-0

Dalgard O; Grebely J; Dore GJ, 2009, 'Hepatitis C virus reinfection following sustained virological response in injection drug users', in Suchtmedizin in Forschung und Praxis, pp. 231 - 234

Sasadeusz J; Dore GJ; Kronborg I; Barton DA; Yoshihara M; Weltman M, 2008, 'PEGYLATED INTERFERON ALFA-2A (PEG-2A) PLUS RIBAVIRIN (RBV) FOR PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) ON OPIOID PHARMACOTHERAPY: VIROLOGICAL OUTCOMES, PSYCHOLOGICAL IMPACT AND SAFETY', in HEPATOLOGY, JOHN WILEY & SONS INC, CA, San Francisco, pp. 894A - 894A, presented at 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, CA, San Francisco, 31 October 2008 - 04 November 2008, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259757401690&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Marks P; Revill PA; Ayres A; Bow-den S; Locarnini S; Thio CL; Ruxrungtham K; Dore GJ, 2008, 'TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS', in HEPATOLOGY, JOHN WILEY & SONS INC, CA, San Francisco, pp. 712A - 713A, presented at 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, CA, San Francisco, 31 October 2008 - 04 November 2008, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259757401290&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Roberts SK; Ngu MC; Strasser SI; George J; Dore GJ; Locarnini SA; Sasadeusz JJ; Sievert W; Elsome AM, 2008, 'Prevalence and nature of viral mutations in chronic hepatitis B patients on antiviral therapy: the charm study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A264 - A264, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259960100179&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Jin F; Prestage G; Dore GJ; Zablotska I; Rawstorne PR; Kippax SC; Kaldor JM; Grulich AE, 2008, 'Prevalence, Incidence and Risk Factors for Hepatitis C in HIV Negative and HIV Positive Homosexual Men', in Sexual Health, CSIRO Publishing, Australia, pp. 20 - 21, presented at Sexual Health, Perth, 17 September 2008 - 20 September 2008

Matthews G; Hellard M; Haber PS; Yeung B; Marks PB; Sasadcusz J; Baker DA; McCaughan G; White PA; Rawlinson WD; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Frequency of RVR and its utility as a predictor of treatment outcome in individuals treated within the Australian Trial in Acute Hepatitis c (ATAHC)', in Journal of Hepatology, Elsevier Science BV, Amsterdam, Netherlands, pp. S303 - S303, presented at Journal of Hepatology

Grebely J; Raffa J; Krajde M; Fischer B; Kerr TH; Dore GJ; Tyndall M, 2008, 'IMPACT OF HEPATITIS C VIRUS INFECTION ON LIVER-RELATED MORTALITY IN A LARGE COMMUNITY-BASED COHORT OF INNER CITY RESIDENTS', in Journal of Hepatology, Elsevier Science BV, Amsterdam, Netherlands, pp. 401 - 402, presented at Journal of Hepatology

Crawford D; Robertson SL; Weltman MD; Cheng W; Sievert W; McCaughan G; Desmond PV; Alston A; DePamphilis J; Marks PB; Dore GJ, 2008, 'Baseline factors associated with rapid and early virological responses in HCV genotype 1 patients treated with induction dosing of pegylated interferon: The CHARIOT study', in Journal of Hepatology, Elsevier Science BV, Amsterdam, Netherlands, pp. S290 - S291, presented at Journal of Hepatology

Matthews G; White PA; Hellard M; Grebely J; Marks P; Yeung B; Kaldor JM; Lloyd AR; Danta M; Dore GJ, 2008, 'Evidence of sexual transmission of hepatitis C virus infection among HIV-positive men who have sex with men in the Australian trial in acute hepatitis C (ATAHC) study', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A365 - A366

Hellard M; Matthews G; Petoumenos K; Grebely J; Haber PS; Van Beek IA; Marks P; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Factors associated with uptake of treatment for acute and early chronic hepatitis C virus infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A344 - A344

Matthews G; Hellard M; Haber PS; Yeung B; Marks P; Rawlinson WD; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Frequency of rapid virological response and its utility as a predictor of treatment outcome in individuals treated within the Australian trial in acute hepatitis C (ATAHC)', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A337 - A337

Flynn J; White PA; Grebely J; Kaldor JM; Hellard M; Dore GJ; Lloyd AR; Ffrench R, 2008, 'Immunity to acute hepatitis C and the influence of early therapy', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A356 - A356

Hellard M; Grebely J; Matthews G; Haber PS; Petoumenos K; Yeung B; Van Beek IA; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Impact of illicit drug use on response to therapy during treatment for acute and early chronic HCV infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A337 - A338

Grebely J; Matthews G; White PA; Renkin M; Flynn J; Ffrench R; Kaldor JM; Hellard M; Lloyd AR; Dore GJ, 2008, 'Incidence and risk factors for HCV reinfection and superinfection in individuals treated for acute/early chronic HCV infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A343 - A344

Matthews G; Grebely J; White PA; Renkin M; Marks PB; Ffrench R; Rawlinson WD; Kaldor JM; Hellard M; Lloyd AR; Dore GJ, 2008, 'INCIDENCE AND RISK FACTORS FOR HCV SUPERINFECTION AND REINFECTION IN INDIVIDUALS TREATED FOR ACUTE/EARLY CHRONIC HCV INFECTION', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1844 - 1845, presented at Hepatology

Grebely J; Ngai T; Knight E; Duncan F; Raffa J; Genoway K; Showler G; Krajden M; Dore GJ; Conway B, 2008, 'Low rate of hepatitis C virus re-infection following sustained virological response among injection drug users having received treatment for HCV infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A338 - A338

Robotin M; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy MT, 2008, 'Modeling population-based chronic hepatitis B screening and treatment to prevent cirrhosis and liver cancer among high risk populations in Australia', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A358 - A359

White PA; Grebely J; Matthews G; Flynn J; Renkin M; Kaldor JM; Lloyd AR; Hellard M; Ffrench R; Dore GJ, 2008, 'Natural history of HCV reinfection and superinfection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A355 - A355

White PA; Grebely J; Flynn J; Matthews G; Renkin M; Yeung B; Rawlinson WD; Kaldor JM; Hellard M; Lloyd AR; Ffrench R; Dore GJ, 2008, 'NATURAL HISTORY OF HCV SUPERINFECTION AND REINFECTION', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1056 - 1057, presented at Hepatology

Sasadeusz J; Dore GJ; Kronborg I; Barton D; Yoshihara M; Weltman M, 2008, 'PEGYLATED INTERFERON ALFA-2A (PEG-2A) PLUS RIBAVIRIN (RBV) FOR PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) ON OPIOID PHARMACOTHERAPY: VIROLOGICAL OUTCOMES, PSYCHOLOGICAL IMPACT AND SAFETY', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1310 - 1311, presented at Hepatology

Nguyen VT; Amin J; Law MG; Dore GJ, 2008, 'Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A343 - A343, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600028&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Jones T; Marks P; Connelly C; Warner S; Fragomeli V; Walker PJ; Ferguson CM; Dore GJ, 2008, 'Predictors of HCV treatment uptake and clinical trial participation among patients newly referred for HCV infection: the HCV clinical audit study', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A241 - A241, presented at Journal of Gastroenterology and Hepatology, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259960100133&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Maher L; Dore G; Treloar C; Rawlinson W; White P; Dolan K; Zekry A; Madden A; Loveday S; Kaldor J; Lloyd A, 2008, 'Preparedness for candidate hepatitis C vaccine trials in people who inject drugs: challenges and opportunities', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A358 - A358

Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Thio C; Bowden SJ; Ayres A; Locarnini S; Ruxrungtham K; Dore GJ, 2008, 'Tenofovir based HAART is associated with high rates of HBV DNA suppression and HBEAG seroconversion in thai HIV-HBV coinfected patients', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A336 - A336, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Marks PB; Revill P; Ayres A; Bow-den S; Locarnini S; Thio C; Ruxrungtham K; Dore GJ, 2008, 'TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 906 - 907, presented at Hepatology

Gidding H; Topp L; Middleton M; Dore G; Robinson K; Maher L; Kaldor J; Law M, 2008, 'The epidemiology of hepatitis C in Australia-a review of notifications, treatment uptake, and associated liver transplantations 1997-2006', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A379 - A379

Audsley J; Littlejohn M; Yuen L; Desmond C; Dore GJ; Ruxrungtham K; Locarnini S; Thio C; Lewin S; Revill P, 2008, 'Virological characteristics of a longitudinal HIV/HBV co-infected cohort prior to initiation of HBV-active HAART', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A336 - A337, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Roberts S; Weltman M; Crawford D; Cheng W; Sievert W; McCaughan GW; Desmond PV; Yoshihara M; Miller JE; Depamphilis J; Marks P; Dore GJ, 2007, 'Rapid and early virological response rates are increased with 12 week 360 mu g/wk peginterferon alfa-2A (40KD) and standard ribavirin in HCV genotype 1 treatment naive patients: Efficacy and safety analysis of the induction phase of the CHARIOT study', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 257A - 258A, presented at 58th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 02 November 2007 - 06 November 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000249910400055&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Roberts S; Cooksley G; Dore G; Robson R; Shaw D; Berns H; Brandt M; Fenner S; Hill G; Ipe D; Klumpp K; Mannino M; O'mara E; Najera I; Tu Y; Washington C, 2007, 'Viral load and ALT reductions associated with R1626 monotherapy, a novel nucleoside analog, in chronic hepatitis C genotype 1 patients', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, DC, Washington, pp. A779 - A779, presented at Digestive Disease Weeking Meeting/ASGE Postgraduate Course Meeting, DC, Washington, 19 May 2007 - 24 May 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000245927606317&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Klumpp K; Smith D; Brandl M; Alfredson T; Sarma K; Smith M; Najera I; Jiang W-R; Le Pogam S; Leveque V; Ma H; Tu Y; Chan R; Chen C-W; Wu X; Birudaraj R; Swallow S; Martin JA; Cammack N; Berns H; Fettner S; Ipe D; Mannino M; O'Mara E; Washington C; Roberts S; Cooksley G; Dore G; Shaw D; Blue DR; Zahm F; Hill G, 2007, 'Design and characterization of R1626, a prodrug of the HCV replication inhibitor R1479 (4'-azidocytidine) with enhanced oral bioavailability', in ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV, CA, Palm Spring, pp. A35 - A35, presented at 20th International Conference on Antiviral Research, CA, Palm Spring, 29 April 2007 - 03 May 2007, http://dx.doi.org/10.1016/j.antiviral.2007.01.029

McCaughan GW; Omata M; Amarapurkar D; Bowden S; Chow WC; Chutaputti A; Dore G; Gane E; Guan R; Hamid SS; Hardikar W; Hui CK; Jafri W; Jia JD; Lai MY; Wei L; Leung N; Piratvisuth T; Sarin S; Sollano J; Tateishi R, 2007, 'Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection', in Journal of Gastroenterology and Hepatology (Australia), pp. 615 - 633, http://dx.doi.org/10.1111/j.1440-1746.2007.04883.x


Back to profile page